These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 15781666)

  • 1. 19-Nor-1,25(OH)2D2 (a novel, noncalcemic vitamin D analogue), combined with arsenic trioxide, has potent antitumor activity against myeloid leukemia.
    Kumagai T; Shih LY; Hughes SV; Desmond JC; O'Kelly J; Hewison M; Koeffler HP
    Cancer Res; 2005 Mar; 65(6):2488-97. PubMed ID: 15781666
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hypoxia-simulating agents and selective stimulation of arsenic trioxide-induced growth arrest and cell differentiation in acute promyelocytic leukemic cells.
    Yan H; Peng ZG; Wu YL; Jiang Y; Yu Y; Huang Y; Zhu YS; Zhao Q; Chen GQ
    Haematologica; 2005 Dec; 90(12):1607-16. PubMed ID: 16330433
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Arsenic trioxide and melarsoprol induce programmed cell death in myeloid leukemia cell lines and function in a PML and PML-RARalpha independent manner.
    Wang ZG; Rivi R; Delva L; König A; Scheinberg DA; Gambacorti-Passerini C; Gabrilove JL; Warrell RP; Pandolfi PP
    Blood; 1998 Sep; 92(5):1497-504. PubMed ID: 9716575
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PIC-1/SUMO-1-modified PML-retinoic acid receptor alpha mediates arsenic trioxide-induced apoptosis in acute promyelocytic leukemia.
    Sternsdorf T; Puccetti E; Jensen K; Hoelzer D; Will H; Ottmann OG; Ruthardt M
    Mol Cell Biol; 1999 Jul; 19(7):5170-8. PubMed ID: 10373566
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Carbonyl reductase 1 offers a novel therapeutic target to enhance leukemia treatment by arsenic trioxide.
    Jang M; Kim Y; Won H; Lim S; K R J; Dashdorj A; Min YH; Kim SY; Shokat KM; Ha J; Kim SS
    Cancer Res; 2012 Aug; 72(16):4214-24. PubMed ID: 22719067
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Arsenic trioxide therapy for relapsed acute promyelocytic leukemia: an useful salvage therapy.
    Huan SY; Yang CH; Chen YC
    Leuk Lymphoma; 2000 Jul; 38(3-4):283-93. PubMed ID: 10830735
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rexinoid-triggered differentiation and tumor-selective apoptosis of acute myeloid leukemia by protein kinase A-mediated desubordination of retinoid X receptor.
    Altucci L; Rossin A; Hirsch O; Nebbioso A; Vitoux D; Wilhelm E; Guidez F; De Simone M; Schiavone EM; Grimwade D; Zelent A; de Thé H; Gronemeyer H
    Cancer Res; 2005 Oct; 65(19):8754-65. PubMed ID: 16204045
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TRIB3 Promotes APL Progression through Stabilization of the Oncoprotein PML-RARα and Inhibition of p53-Mediated Senescence.
    Li K; Wang F; Cao WB; Lv XX; Hua F; Cui B; Yu JJ; Zhang XW; Shang S; Liu SS; Yu JM; Han MZ; Huang B; Zhang TT; Li X; Jiang JD; Hu ZW
    Cancer Cell; 2017 May; 31(5):697-710.e7. PubMed ID: 28486108
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Azacytidine sensitizes acute myeloid leukemia cells to arsenic trioxide by up-regulating the arsenic transporter aquaglyceroporin 9.
    Chau D; Ng K; Chan TS; Cheng YY; Fong B; Tam S; Kwong YL; Tse E
    J Hematol Oncol; 2015 May; 8():46. PubMed ID: 25953102
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synergistic Leukemia Eradication by Combined Treatment with Retinoic Acid and HIF Inhibition by EZN-2208 (PEG-SN38) in Preclinical Models of PML-RARα and PLZF-RARα-Driven Leukemia.
    Coltella N; Valsecchi R; Ponente M; Ponzoni M; Bernardi R
    Clin Cancer Res; 2015 Aug; 21(16):3685-94. PubMed ID: 25931453
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted removal of PML-RARalpha protein is required prior to inhibition of histone deacetylase for overcoming all-trans retinoic acid differentiation resistance in acute promyelocytic leukemia.
    Jing Y; Xia L; Waxman S
    Blood; 2002 Aug; 100(3):1008-13. PubMed ID: 12130515
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Potentiation of arsenic trioxide-induced apoptosis by retinoic acid in retinoic acid sensitive and resistant HL-60 myeloid leukemia cells].
    Huang X
    Chin Med J (Engl); 2000 Jun; 113(6):498-501. PubMed ID: 11775865
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Understanding the molecular pathogenesis of acute promyelocytic leukemia.
    Lo-Coco F; Hasan SK
    Best Pract Res Clin Haematol; 2014 Mar; 27(1):3-9. PubMed ID: 24907012
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination of a potent 20-epi-vitamin D3 analogue (KH 1060) with 9-cis-retinoic acid irreversibly inhibits clonal growth, decreases bcl-2 expression, and induces apoptosis in HL-60 leukemic cells.
    Elstner E; Linker-Israeli M; Umiel T; Le J; Grillier I; Said J; Shintaku IP; Krajewski S; Reed JC; Binderup L; Koeffler HP
    Cancer Res; 1996 Aug; 56(15):3570-6. PubMed ID: 8758928
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of all-trans retinoic acid and arsenic trioxide on tissue factor expression in acute promyelocytic leukemia cells.
    Guo W; Wang H; Zhao W; Zhu J; Ju B; Wang X
    Chin Med J (Engl); 2001 Jan; 114(1):30-4. PubMed ID: 11779431
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Leukemia-associated translocation products able to activate RAS modify PML and render cells sensitive to arsenic-induced apoptosis.
    Puccetti E; Beissert T; Güller S; Li JE; Hoelzer D; Ottmann OG; Ruthardt M
    Oncogene; 2003 Oct; 22(44):6900-8. PubMed ID: 14534537
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TRAIL decoy receptors mediate resistance of acute myeloid leukemia cells to TRAIL.
    Riccioni R; Pasquini L; Mariani G; Saulle E; Rossini A; Diverio D; Pelosi E; Vitale A; Chierichini A; Cedrone M; Foà R; Lo Coco F; Peschle C; Testa U
    Haematologica; 2005 May; 90(5):612-24. PubMed ID: 15921376
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Retinoic acid, but not arsenic trioxide, degrades the PLZF/RARalpha fusion protein, without inducing terminal differentiation or apoptosis, in a RA-therapy resistant t(11;17)(q23;q21) APL patient.
    Koken MH; Daniel MT; Gianni M; Zelent A; Licht J; Buzyn A; Minard P; Degos L; Varet B; de Thé H
    Oncogene; 1999 Jan; 18(4):1113-8. PubMed ID: 10023688
    [TBL] [Abstract][Full Text] [Related]  

  • 19. AML-associated translocation products block vitamin D(3)-induced differentiation by sequestering the vitamin D(3) receptor.
    Puccetti E; Obradovic D; Beissert T; Bianchini A; Washburn B; Chiaradonna F; Boehrer S; Hoelzer D; Ottmann OG; Pelicci PG; Nervi C; Ruthardt M
    Cancer Res; 2002 Dec; 62(23):7050-8. PubMed ID: 12460926
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of Myc in differentiation and apoptosis in HL60 cells after exposure to arsenic trioxide or all-trans retinoic acid.
    Jiang G; Albihn A; Tang T; Tian Z; Henriksson M
    Leuk Res; 2008 Feb; 32(2):297-307. PubMed ID: 17706770
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.